阿帕替尼对肝细胞癌治疗研究进展

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (2): 48-51.

阿帕替尼对肝细胞癌治疗研究进展

赵浩然, 张玉宝^*

哈尔滨医科大学附属肿瘤医院肝胆外科,黑龙江哈尔滨 150081

收稿日期:2020-05-11 出版日期:2020-06-30 发布日期:2020-07-23
通讯作者: ^* 张玉宝 E-mail: Zhyb88077@sina.com
作者简介:张玉宝,教授,哈尔滨医科大学附属肿瘤医院肝胆外科。
基金资助:
北京医学奖励基金（yxjl-2020-0070-0006）

Research progress of apatinib in treatment of hepatocellular carcinoma

Zhao Haoran, Zhang Yubao^*

Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081, Heilongjiang, China

Received:2020-05-11 Online:2020-06-30 Published:2020-07-23

摘要/Abstract

摘要： 多年来原发性肝癌在中国的发生率及死亡率均一直处在前五位,且复发率高,预后不良。基于国内情况,原发性肝癌发生的病理类型以肝炎相关的肝细胞癌（hepatocellular carcinoma,HCC）为主,故而HCC研究对原发性肝癌的攻坚有着至关重要的临床意义与研究价值。阿帕替尼作为国内自主研发的小分子VEGFR酪氨酸激酶抑制剂,其对HCC治疗的安全性、有效性不断在临床治疗中得以验证,具有可观的研究潜力与前景,本文就目前阿帕替尼在HCC的应用现状及研究进展进行阐述,旨在为临床应用提出有价值的参考依据。

关键词: 阿帕替尼, 肝细胞癌, 研究进展

Abstract: For many years, the incidence and mortality of primary liver cancer in China have been in the top five, with high recurrence rate and poor prognosis. Based on China's national conditions, the pathological type of primary liver cancer is mainly hepatitis-related hepatocellular carcinoma (HCC). Therefore, the research for HCC can provide crucial reference on the treatment and research on primary liver cancer. Apatinib is a small molecule VEGFR tyrosine kinase inhibitor independently developed in our country. Its safety and effectiveness in HCC treatment have been continuously verified in clinical treatments. It has considerable research potential and prospect. This article reviews the current application status and research progress of apatinib in HCC, aiming to provide valuable reference basis for clinical application.

Key words: Apatinib, Hepatocellular carcinoma, Research progress

赵浩然, 张玉宝. 阿帕替尼对肝细胞癌治疗研究进展[J]. 肝癌电子杂志, 2020, 7(2): 48-51.

Zhao Haoran, Zhang Yubao. Research progress of apatinib in treatment of hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 48-51.

参考文献

[1] 王宁, 刘硕, 杨雷, 等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2019, 5(1):87-97.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] 国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019 年版)[J]. 肝癌电子杂志,2020, 7(1):5-23.
[4] ZHANG HJ.Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Therapy, 2015, 9:6075-6081.
[5] LI J, ZHAO XM, CHEN L, et al.Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC cancer, 2010, 10:529.
[6] MATSUMOTO K, HORIE S, ISHIKAWA H, et al.Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa[J]. Life Sci, 2004, 74(17):2143-2155.
[7] LI XJ, XU AJ, LI HH, et al.Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5):1693-1701.
[8] HSIEH FC, CHENG G, LIN J.Evaluation of potential Stat3-regulated genes in human breast cancer[J]. Biochem Biophys Res Commun, 2005, 335(2):292-299.
[9] DING J, CHENG XY, LIU S, et al.Apatinib exerts anti-tumour effects on ovarian cancer cells[J]. Gynecol oncol, 2019, 153(1):165-174.
[10] KOCH S, TUGUES S, LI XJ, et al.Signal transduction by vascular endothelial growth factor receptors[J]. Biochem J, 2011, 437(2):169-183.
[11] SCOTT AJ, MESSERSMITH WA, JIMENO A, et al.Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs Today(Barc), 2015, 51(4):223-229.
[12] XIE H, TIAN ST, YU HP, et al.A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma[J]. Onco Targets Ther, 2018, 11:3257-3265.
[13] 宋锦添, 陈奕贵, 许春伟, 等. 阿帕替尼治疗53例晚期原发性肝癌的疗效[J].临床与病理杂志, 2017, 37(3):557-563.
[14] 秦叔逵,白玉贤, 欧阳学农,等. 阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J]. 临床肿瘤学杂志, 2017, 22(12):1057-1065.
[15] ZHANG YQ, FAN WZ, WANG Y, et al.Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study[J]. Cancer Control, 2019, 26(1):1073274819872216.
[16] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in Advanced Hepatocellular Carcinoma Reply[J]. N Engl J Med, 2008, 359(23):2498-2499.
[17] CHENG AL, KANG YK, CHEN ZD, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[18] ZHU YX, FENG B, MEI L, et al.Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma[J]. J BUON, 2019, 24(2):608-614.
[19] FAN WZ, YUAN GS, FAN HS, et al.Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study[J]. Clin Ther, 2019, 41(8):1463-1476.
[20] XU JM, ZHANG Y, JIA R, et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2):515-523.
[21] 甄振华, 申传厚, 杜文凯. 阿帕替尼联合槐耳颗粒治疗晚期原发性肝癌的临床疗效[J]. 现代肿瘤医学, 2019, 27(17):3086-3089.
[22] 秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847.
[23] EREMINA V, JEFFERSON JA, KOWALEWSKA J, et al.VEGF inhibition and renal thrombotic microangiopathy[J]. N Engl J Med, 2008, 358(11):1129-1136.
[24] 李萍, 贾乐川, 付岩, 等. 甲磺酸阿帕替尼不良反应中文文献分析[J]. 中国医院药学杂志, 40(5):546-548.
[25] MCLELLAN B, KERR H.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib[J]. Dermatol ther, 2011, 24(4):396-400.
[26] 何苗苗, 谢六生, 刘光斌, 等. 151例阿帕替尼致药品不良反应国内文献分析[J].中国药师, 2019, 22(11):2086-2089.